<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198756</url>
  </required_header>
  <id_info>
    <org_study_id>113314</org_study_id>
    <nct_id>NCT01198756</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is designed to test the immunogenicity and safety of an investigational influenza
      vaccine, in children compared to two other influenza vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1, 2010</start_date>
  <completion_date type="Actual">July 1, 2011</completion_date>
  <primary_completion_date type="Actual">July 1, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted Against 4 Strains of Influenza Disease</measure>
    <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains assessed were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 flu strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination (at Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects (POST)) compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer). The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease - By Age Strata</measure>
    <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted Against 4 Strains of Influenza Disease - By Age Strata</measure>
    <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains assessed were A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected Against 4 Strains of Influenza Disease - By Age Strata</measure>
    <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition Antibodies Against 4 Strains of Influenza Disease - By Age Strata</measure>
    <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer). The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Vaccination</measure>
    <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity grade. Grade 3 pain for subjects &lt; 5 years of age = Cried when limb was moved/spontaneously painful; Grade 3 pain for subjects ≥ 5 years of age = Significant pain at rest, pain that preventeded normal everyday activities. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited Local Symptoms After Vaccination</measure>
    <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2 respectively. Solicited local symptoms assessed for duration were pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Below 5 Years of Age With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <description>Symptoms assessed were drowsiness, irritability, loss of appetite and temperature. Any = Incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Any temperature = Axillary temperature ≥ 38.0 degrees Celsius (°C). Grade 3 temperature = Axillary temperature ≥ 39.0°C. Grade 3 irritability = Crying that could not be comforted/ preventing normal activity. Grade 3 drowsiness = Drowsiness preventing normal activity. Grade 3 loss of appetite = Not eating at all. Related = A general symptom assessed by the investigator as causally related to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects 5 Years of Age and Above With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <description>Solicited general symptoms assessed were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering and temperature. Any = Incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Any temperature = axillary temperature ≥ 38.0 °C. Grade 3 temperature = axillary temperature ≥ 39.0°C. Grade 3 symptom = Symptom that prevented normal activity. Related = A general symptom assessed by the investigator as causally related to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited General Symptoms After Vaccination in Subjects Below 5 Years of Age</measure>
    <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2, respectively. Solicited general symptoms assessed for duration in subjects below 5 years of age were drowsiness, irritability and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited General Symptoms After Vaccination in Subjects 5 Years of Age and Above</measure>
    <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2, respectively. Solicited general symptoms assessed for duration in subjects 5 years of age and above were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches and shivering.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Fever in All Subjects Regardless of Their Age After Vaccination</measure>
    <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <description>Duration for fever was assessed via tabulation of the number of days with local symptoms of fever (axillary temperature ≥ 38°C) after vaccination with Dose 1 and Dose 2, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 28-day follow-up period (Day 0-27) after vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE(s) = Occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 unsolicited AE = Occurrence of any unsolicited AE that prevented normal activities. Related unsolicited AE(s) = Occurrence of an unsolicited AE assessed by the investigator to be causally related to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs) After Vaccination</measure>
    <time_frame>During the entire study period (from Day 0 to Day 180)</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Any pIMD(s) = Occurrence of any pIMD(s) regardless of intensity grade or relation to vaccination. Related pIMD(s) = pIMD assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Medically-attended Adverse Events (MAEs) After Vaccination</measure>
    <time_frame>During the entire study period (from Day 0 to Day 180)</time_frame>
    <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other criterion for serious adverse event (SAE)), it was reported as SAE. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.Relationship to vaccination was not assessed for MAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (from Day 0 to Day 180)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE(s) = Occurrence of any SAE(s) regardless of intensity grade or relation to vaccination. Related SAE(s)= Occurrence of any SAE(s) assessed by the investigator as causally related to vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3109</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK2282512A 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Victoria strain Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yamagata strain Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2282512A 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent seasonal influenza vaccine GSK2282512A</intervention_name>
    <description>For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.</description>
    <arm_group_label>GSK2282512A 1 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™ VB</intervention_name>
    <description>For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.</description>
    <arm_group_label>Victoria strain Fluarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™ YB</intervention_name>
    <description>For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose</description>
    <arm_group_label>Yamagata strain Fluarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent seasonal influenza vaccine GSK2282512A</intervention_name>
    <description>Single intramuscular dose for primed subjects, two doses for unprimed subjects.</description>
    <arm_group_label>GSK2282512A 2 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parent(s) or legally
             acceptable representative(s) can and will comply with the requirements of the
             protocol.

          -  A male or female child aged between 6 months and 17 years inclusive at the time of the
             first vaccination; children are eligible regardless of history of administration of
             influenza vaccine in a previous season.

          -  Written informed consent obtained from the subject/from the parent(s)/legally
             acceptable representative(s) of the subject.

          -  Written informed assent obtained from the subject if/as required by local regulations.

          -  Subjects in stable health as determined by investigator's clinical examination and
             assessment of subjects' medical history.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the subject

               -  Has practiced adequate contraception for 30 days prior to vaccination, and

               -  Has a negative pregnancy urine test on the day of vaccination, and

               -  Has agreed to continue adequate contraception during the entire treatment period
                  and for 2 months after completion of the vaccination series.

        Exclusion Criteria:

          -  Child in care

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.Prior receipt of any seasonal or pandemic influenza vaccine within 6
             months preceding the first dose of study vaccine, or planned use during the study
             period.

          -  Chronic administration of immunosuppressants or other immune modifying drugs within
             six months prior to the first vaccine dose.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  History of Guillain-Barré syndrome within 6 weeks of receipt of prior influenza
             vaccine.

          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of
             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse
             reaction to a previous influenza vaccine.

          -  Fever at the time of enrolment.

          -  Acute disease at the time of enrolment.

          -  Any significant disorder of coagulation or treatment with Coumadin derivatives or
             heparin.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Ongoing aspirin therapy.

          -  Any other condition which, in the opinion of the Investigator, prevents the subject
             from participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85288</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hermitage</city>
        <state>Pennsylvania</state>
        <zip>16148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>29812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1N 5B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico city</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alcala de Guadaira</city>
        <zip>41500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pozuelo De Alarcón/Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <results_first_submitted>December 6, 2012</results_first_submitted>
  <results_first_submitted_qc>February 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2013</results_first_posted>
  <disposition_first_submitted>July 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2012</disposition_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113314</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113314</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113314</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113314</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113314</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113314</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113314</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 3109 subjects were enrolled, out of which solely 3094 subjects were vaccinated who constituted the analysed population in this study.</recruitment_details>
      <pre_assignment_details>Unprimed Subjects – subjects aged 6 months to 8 years with no H1N1 vaccine or H1N1 infection in the last season, or with no seasonal influenza vaccine in the past or who had received only 1 dose for the first time in the last season – received a 2-dose vaccination course. Primed Subjects – all other subjects – received a 1-dose vaccination course.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2282512A 1 Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Victoria Strain Fluarix Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Yamagata Strain Fluarix Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>GSK2282512A 2 Group</title>
          <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="932"/>
                <participants group_id="P2" count="929"/>
                <participants group_id="P3" count="932"/>
                <participants group_id="P4" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="894"/>
                <participants group_id="P2" count="889"/>
                <participants group_id="P3" count="902"/>
                <participants group_id="P4" count="275"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2282512A 1 Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Victoria Strain Fluarix Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Yamagata Strain Fluarix Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>GSK2282512A 2 Group</title>
          <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="932"/>
            <count group_id="B2" value="929"/>
            <count group_id="B3" value="932"/>
            <count group_id="B4" value="301"/>
            <count group_id="B5" value="3094"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="4.21"/>
                    <measurement group_id="B2" value="8.9" spread="4.23"/>
                    <measurement group_id="B3" value="8.9" spread="4.17"/>
                    <measurement group_id="B4" value="1.2" spread="0.73"/>
                    <measurement group_id="B5" value="8.1" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="434"/>
                    <measurement group_id="B2" value="455"/>
                    <measurement group_id="B3" value="464"/>
                    <measurement group_id="B4" value="143"/>
                    <measurement group_id="B5" value="1496"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="498"/>
                    <measurement group_id="B2" value="474"/>
                    <measurement group_id="B3" value="468"/>
                    <measurement group_id="B4" value="158"/>
                    <measurement group_id="B5" value="1598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
        <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="878"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="878"/>
                <count group_id="O4" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362.7" lower_limit="335.3" upper_limit="392.3"/>
                    <measurement group_id="O2" value="429.1" lower_limit="396.5" upper_limit="464.3"/>
                    <measurement group_id="O3" value="420.2" lower_limit="388.8" upper_limit="454.0"/>
                    <measurement group_id="O4" value="200.9" lower_limit="166.6" upper_limit="242.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.7" lower_limit="134.2" upper_limit="153.9"/>
                    <measurement group_id="O2" value="139.6" lower_limit="130.5" upper_limit="149.3"/>
                    <measurement group_id="O3" value="151.0" lower_limit="141.0" upper_limit="161.6"/>
                    <measurement group_id="O4" value="61.4" lower_limit="53.8" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=878;871;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.5" lower_limit="230.8" upper_limit="272.0"/>
                    <measurement group_id="O2" value="245.4" lower_limit="226.9" upper_limit="265.4"/>
                    <measurement group_id="O3" value="68.1" lower_limit="61.9" upper_limit="74.9"/>
                    <measurement group_id="O4" value="127.3" lower_limit="109.4" upper_limit="148.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512.5" lower_limit="477.6" upper_limit="549.9"/>
                    <measurement group_id="O2" value="197.0" lower_limit="180.7" upper_limit="214.8"/>
                    <measurement group_id="O3" value="579.0" lower_limit="541.2" upper_limit="619.3"/>
                    <measurement group_id="O4" value="192.7" lower_limit="172.1" upper_limit="215.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted Against 4 Strains of Influenza Disease</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains assessed were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
        <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted Against 4 Strains of Influenza Disease</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains assessed were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="876"/>
                <count group_id="O2" value="870"/>
                <count group_id="O3" value="877"/>
                <count group_id="O4" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, POST (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="739"/>
                    <measurement group_id="O2" value="755"/>
                    <measurement group_id="O3" value="750"/>
                    <measurement group_id="O4" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=876;870;876;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614"/>
                    <measurement group_id="O2" value="590"/>
                    <measurement group_id="O3" value="610"/>
                    <measurement group_id="O4" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=876;870;876;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653"/>
                    <measurement group_id="O2" value="622"/>
                    <measurement group_id="O3" value="262"/>
                    <measurement group_id="O4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659"/>
                    <measurement group_id="O2" value="359"/>
                    <measurement group_id="O3" value="644"/>
                    <measurement group_id="O4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
        <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="878"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="878"/>
                <count group_id="O4" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, Day 0 (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" lower_limit="26.8" upper_limit="32.2"/>
                    <measurement group_id="O2" value="32.2" lower_limit="29.4" upper_limit="35.3"/>
                    <measurement group_id="O3" value="29.1" lower_limit="26.6" upper_limit="31.8"/>
                    <measurement group_id="O4" value="16.8" lower_limit="13.9" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362.7" lower_limit="335.3" upper_limit="392.3"/>
                    <measurement group_id="O2" value="429.1" lower_limit="396.5" upper_limit="464.3"/>
                    <measurement group_id="O3" value="420.2" lower_limit="388.8" upper_limit="454.0"/>
                    <measurement group_id="O4" value="200.9" lower_limit="166.6" upper_limit="242.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 0 (N=876;870;876;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="16.7" upper_limit="19.7"/>
                    <measurement group_id="O2" value="19.0" lower_limit="17.4" upper_limit="20.6"/>
                    <measurement group_id="O3" value="19.4" lower_limit="17.8" upper_limit="21.1"/>
                    <measurement group_id="O4" value="5.6" lower_limit="5.3" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.7" lower_limit="134.2" upper_limit="153.9"/>
                    <measurement group_id="O2" value="139.6" lower_limit="130.5" upper_limit="149.3"/>
                    <measurement group_id="O3" value="151.0" lower_limit="141.0" upper_limit="161.6"/>
                    <measurement group_id="O4" value="61.4" lower_limit="53.8" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, Day 0 (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="22.5" upper_limit="27.3"/>
                    <measurement group_id="O2" value="25.8" lower_limit="23.5" upper_limit="28.4"/>
                    <measurement group_id="O3" value="25.8" lower_limit="23.5" upper_limit="28.4"/>
                    <measurement group_id="O4" value="8.7" lower_limit="7.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=878;871;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.5" lower_limit="230.8" upper_limit="272.0"/>
                    <measurement group_id="O2" value="245.4" lower_limit="226.9" upper_limit="265.4"/>
                    <measurement group_id="O3" value="68.1" lower_limit="61.9" upper_limit="74.9"/>
                    <measurement group_id="O4" value="127.3" lower_limit="109.4" upper_limit="148.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, Day 0 (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="52.0" upper_limit="64.4"/>
                    <measurement group_id="O2" value="58.4" lower_limit="52.6" upper_limit="64.9"/>
                    <measurement group_id="O3" value="65.9" lower_limit="59.3" upper_limit="73.2"/>
                    <measurement group_id="O4" value="7.7" lower_limit="7.0" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512.5" lower_limit="477.6" upper_limit="549.9"/>
                    <measurement group_id="O2" value="197.0" lower_limit="180.7" upper_limit="214.8"/>
                    <measurement group_id="O3" value="579.0" lower_limit="541.2" upper_limit="619.3"/>
                    <measurement group_id="O4" value="192.7" lower_limit="172.1" upper_limit="215.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected Against 4 Strains of Influenza Disease</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 flu strains.</description>
        <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected Against 4 Strains of Influenza Disease</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 flu strains.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="878"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="878"/>
                <count group_id="O4" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, Day 0 (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480"/>
                    <measurement group_id="O2" value="496"/>
                    <measurement group_id="O3" value="477"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="850"/>
                    <measurement group_id="O2" value="848"/>
                    <measurement group_id="O3" value="848"/>
                    <measurement group_id="O4" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 0 (N=876;870;876;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="301"/>
                    <measurement group_id="O3" value="324"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="816"/>
                    <measurement group_id="O2" value="808"/>
                    <measurement group_id="O3" value="819"/>
                    <measurement group_id="O4" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, Day 0 (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                    <measurement group_id="O2" value="404"/>
                    <measurement group_id="O3" value="400"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=878;871;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="838"/>
                    <measurement group_id="O2" value="839"/>
                    <measurement group_id="O3" value="643"/>
                    <measurement group_id="O4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, Day 0 (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="578"/>
                    <measurement group_id="O2" value="583"/>
                    <measurement group_id="O3" value="622"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=878;871;878;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869"/>
                    <measurement group_id="O2" value="805"/>
                    <measurement group_id="O3" value="873"/>
                    <measurement group_id="O4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination (at Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects (POST)) compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer). The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains</description>
        <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination (at Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects (POST)) compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer). The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="876"/>
                <count group_id="O2" value="870"/>
                <count group_id="O3" value="877"/>
                <count group_id="O4" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, POST (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.31" lower_limit="11.34" upper_limit="13.35"/>
                    <measurement group_id="O2" value="13.31" lower_limit="12.28" upper_limit="14.43"/>
                    <measurement group_id="O3" value="14.42" lower_limit="13.27" upper_limit="15.66"/>
                    <measurement group_id="O4" value="11.95" lower_limit="10.52" upper_limit="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=876;870;876;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" lower_limit="7.30" upper_limit="8.64"/>
                    <measurement group_id="O2" value="7.37" lower_limit="6.78" upper_limit="8.02"/>
                    <measurement group_id="O3" value="7.78" lower_limit="7.16" upper_limit="8.46"/>
                    <measurement group_id="O4" value="10.94" lower_limit="9.64" upper_limit="12.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=876;870;876;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.12" lower_limit="9.23" upper_limit="11.09"/>
                    <measurement group_id="O2" value="9.51" lower_limit="8.64" upper_limit="10.45"/>
                    <measurement group_id="O3" value="2.63" lower_limit="2.47" upper_limit="2.81"/>
                    <measurement group_id="O4" value="14.61" lower_limit="12.84" upper_limit="16.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=876;870;877;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" lower_limit="8.12" upper_limit="9.66"/>
                    <measurement group_id="O2" value="3.37" lower_limit="3.14" upper_limit="3.62"/>
                    <measurement group_id="O3" value="8.78" lower_limit="8.05" upper_limit="9.58"/>
                    <measurement group_id="O4" value="24.92" lower_limit="21.98" upper_limit="28.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease - By Age Strata</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
        <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 1 (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease - By Age Strata</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. Antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="453"/>
                <count group_id="O3" value="424"/>
                <count group_id="O4" value="447"/>
                <count group_id="O5" value="424"/>
                <count group_id="O6" value="454"/>
                <count group_id="O7" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, Day 0 (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="21.6" upper_limit="28.3"/>
                    <measurement group_id="O2" value="34.6" lower_limit="30.6" upper_limit="39.2"/>
                    <measurement group_id="O3" value="26.9" lower_limit="23.5" upper_limit="30.9"/>
                    <measurement group_id="O4" value="38.2" lower_limit="33.8" upper_limit="43.1"/>
                    <measurement group_id="O5" value="24.5" lower_limit="21.5" upper_limit="27.8"/>
                    <measurement group_id="O6" value="34.2" lower_limit="30.3" upper_limit="38.6"/>
                    <measurement group_id="O7" value="16.8" lower_limit="13.9" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, POST (N=425;453;424;447;424;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.5" lower_limit="274.9" upper_limit="350.6"/>
                    <measurement group_id="O2" value="419.5" lower_limit="379.8" upper_limit="463.4"/>
                    <measurement group_id="O3" value="382.7" lower_limit="339.4" upper_limit="431.6"/>
                    <measurement group_id="O4" value="478.2" lower_limit="431.4" upper_limit="530.0"/>
                    <measurement group_id="O5" value="356.2" lower_limit="316.5" upper_limit="400.8"/>
                    <measurement group_id="O6" value="490.3" lower_limit="443.7" upper_limit="541.7"/>
                    <measurement group_id="O7" value="200.9" lower_limit="166.6" upper_limit="242.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 0 (N=423;453;423;447;423;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" lower_limit="17.4" upper_limit="22.4"/>
                    <measurement group_id="O2" value="16.7" lower_limit="15.0" upper_limit="18.7"/>
                    <measurement group_id="O3" value="21.2" lower_limit="18.6" upper_limit="24.2"/>
                    <measurement group_id="O4" value="17.0" lower_limit="15.3" upper_limit="19.0"/>
                    <measurement group_id="O5" value="20.2" lower_limit="17.8" upper_limit="23.0"/>
                    <measurement group_id="O6" value="18.6" lower_limit="16.6" upper_limit="20.9"/>
                    <measurement group_id="O7" value="5.6" lower_limit="5.3" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=425;453;424;447;424;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" lower_limit="123.7" upper_limit="154.5"/>
                    <measurement group_id="O2" value="149.1" lower_limit="137.3" upper_limit="162.0"/>
                    <measurement group_id="O3" value="144.4" lower_limit="130.6" upper_limit="159.7"/>
                    <measurement group_id="O4" value="135.2" lower_limit="123.5" upper_limit="148.0"/>
                    <measurement group_id="O5" value="147.9" lower_limit="133.3" upper_limit="164.1"/>
                    <measurement group_id="O6" value="153.9" lower_limit="140.7" upper_limit="168.4"/>
                    <measurement group_id="O7" value="61.4" lower_limit="53.8" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, Day 0 (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="15.8" upper_limit="21.1"/>
                    <measurement group_id="O2" value="32.9" lower_limit="29.0" upper_limit="37.4"/>
                    <measurement group_id="O3" value="20.2" lower_limit="17.6" upper_limit="23.3"/>
                    <measurement group_id="O4" value="32.5" lower_limit="28.7" upper_limit="36.8"/>
                    <measurement group_id="O5" value="18.4" lower_limit="16.0" upper_limit="21.1"/>
                    <measurement group_id="O6" value="35.4" lower_limit="31.3" upper_limit="40.1"/>
                    <measurement group_id="O7" value="8.7" lower_limit="7.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=425;453;424;447;423;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.4" lower_limit="171.3" upper_limit="220.7"/>
                    <measurement group_id="O2" value="317.8" lower_limit="287.1" upper_limit="351.8"/>
                    <measurement group_id="O3" value="197.4" lower_limit="175.9" upper_limit="221.6"/>
                    <measurement group_id="O4" value="301.7" lower_limit="272.2" upper_limit="334.3"/>
                    <measurement group_id="O5" value="52.6" lower_limit="45.2" upper_limit="61.2"/>
                    <measurement group_id="O6" value="86.6" lower_limit="77.4" upper_limit="96.9"/>
                    <measurement group_id="O7" value="127.3" lower_limit="109.4" upper_limit="148.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, Day 0 (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="23.8" upper_limit="31.7"/>
                    <measurement group_id="O2" value="116.2" lower_limit="102.2" upper_limit="132.1"/>
                    <measurement group_id="O3" value="29.5" lower_limit="25.6" upper_limit="34.0"/>
                    <measurement group_id="O4" value="111.6" lower_limit="98.3" upper_limit="126.8"/>
                    <measurement group_id="O5" value="29.5" lower_limit="25.5" upper_limit="34.1"/>
                    <measurement group_id="O6" value="139.6" lower_limit="124.6" upper_limit="156.4"/>
                    <measurement group_id="O7" value="7.7" lower_limit="7.0" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=425;453;424;447;424;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.4" lower_limit="327.8" upper_limit="402.9"/>
                    <measurement group_id="O2" value="707.5" lower_limit="648.7" upper_limit="771.5"/>
                    <measurement group_id="O3" value="103.2" lower_limit="91.7" upper_limit="116.1"/>
                    <measurement group_id="O4" value="363.7" lower_limit="330.4" upper_limit="400.3"/>
                    <measurement group_id="O5" value="416.7" lower_limit="374.5" upper_limit="463.7"/>
                    <measurement group_id="O6" value="787.1" lower_limit="731.3" upper_limit="847.2"/>
                    <measurement group_id="O7" value="192.7" lower_limit="172.1" upper_limit="215.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted Against 4 Strains of Influenza Disease - By Age Strata</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains assessed were A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
        <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 1 (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted Against 4 Strains of Influenza Disease - By Age Strata</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The vaccine strains assessed were A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="453"/>
                <count group_id="O3" value="423"/>
                <count group_id="O4" value="447"/>
                <count group_id="O5" value="424"/>
                <count group_id="O6" value="453"/>
                <count group_id="O7" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, POST (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                    <measurement group_id="O2" value="365"/>
                    <measurement group_id="O3" value="390"/>
                    <measurement group_id="O4" value="365"/>
                    <measurement group_id="O5" value="380"/>
                    <measurement group_id="O6" value="370"/>
                    <measurement group_id="O7" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=423;453;423;447;423;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="323"/>
                    <measurement group_id="O3" value="282"/>
                    <measurement group_id="O4" value="308"/>
                    <measurement group_id="O5" value="296"/>
                    <measurement group_id="O6" value="314"/>
                    <measurement group_id="O7" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=423;453;423;447;423;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                    <measurement group_id="O2" value="324"/>
                    <measurement group_id="O3" value="326"/>
                    <measurement group_id="O4" value="296"/>
                    <measurement group_id="O5" value="133"/>
                    <measurement group_id="O6" value="129"/>
                    <measurement group_id="O7" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="293"/>
                    <measurement group_id="O3" value="181"/>
                    <measurement group_id="O4" value="178"/>
                    <measurement group_id="O5" value="372"/>
                    <measurement group_id="O6" value="272"/>
                    <measurement group_id="O7" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected Against 4 Strains of Influenza Disease - By Age Strata</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
        <time_frame>At Day 0 and at 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 1 (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected Against 4 Strains of Influenza Disease - By Age Strata</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable and eligible subjects for whom data concerning immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="453"/>
                <count group_id="O3" value="424"/>
                <count group_id="O4" value="447"/>
                <count group_id="O5" value="424"/>
                <count group_id="O6" value="454"/>
                <count group_id="O7" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, Day 0 (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="271"/>
                    <measurement group_id="O3" value="218"/>
                    <measurement group_id="O4" value="278"/>
                    <measurement group_id="O5" value="207"/>
                    <measurement group_id="O6" value="270"/>
                    <measurement group_id="O7" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, POST (N=425;453;424;447;424;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                    <measurement group_id="O2" value="445"/>
                    <measurement group_id="O3" value="412"/>
                    <measurement group_id="O4" value="436"/>
                    <measurement group_id="O5" value="405"/>
                    <measurement group_id="O6" value="443"/>
                    <measurement group_id="O7" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 0 (N=423;453;423;447;423;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="174"/>
                    <measurement group_id="O4" value="127"/>
                    <measurement group_id="O5" value="168"/>
                    <measurement group_id="O6" value="156"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=425;453;424;447;424;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="437"/>
                    <measurement group_id="O3" value="390"/>
                    <measurement group_id="O4" value="418"/>
                    <measurement group_id="O5" value="389"/>
                    <measurement group_id="O6" value="430"/>
                    <measurement group_id="O7" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, Day 0 (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="244"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="241"/>
                    <measurement group_id="O5" value="150"/>
                    <measurement group_id="O6" value="250"/>
                    <measurement group_id="O7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=425;453;424;447;423;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                    <measurement group_id="O2" value="440"/>
                    <measurement group_id="O3" value="406"/>
                    <measurement group_id="O4" value="433"/>
                    <measurement group_id="O5" value="271"/>
                    <measurement group_id="O6" value="372"/>
                    <measurement group_id="O7" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, Day 0 (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="373"/>
                    <measurement group_id="O3" value="209"/>
                    <measurement group_id="O4" value="374"/>
                    <measurement group_id="O5" value="220"/>
                    <measurement group_id="O6" value="402"/>
                    <measurement group_id="O7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=425;453;424;447;424;454;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419"/>
                    <measurement group_id="O2" value="450"/>
                    <measurement group_id="O3" value="361"/>
                    <measurement group_id="O4" value="444"/>
                    <measurement group_id="O5" value="420"/>
                    <measurement group_id="O6" value="453"/>
                    <measurement group_id="O7" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition Antibodies Against 4 Strains of Influenza Disease - By Age Strata</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer). The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
        <time_frame>At 28 days after administration of the last vaccine dose (Day 28 for Primed Subjects and at Day 56 for Unprimed Subjects) (POST)</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 1 (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain Fluarix (3-8 Years) Group</title>
            <description>Subjects, 3 to 8 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain Fluarix (9-17 Years) Group</title>
            <description>Subjects, 9 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition Antibodies Against 4 Strains of Influenza Disease - By Age Strata</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer). The 4 assessed influenza strains were the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria) and B/Florida/4/2006 (Yamagata) flu strains. Subjects were assessed according to 3 age categories, 3-8 years, 9-17 years and 6-35 months.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, inclusive of all evaluable and eligible subjects with immunogenicity results available for antibodies against at least one study vaccine component after vaccination, solely on subjects with both pre- and post-vaccination immunogenicity results available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="453"/>
                <count group_id="O3" value="423"/>
                <count group_id="O4" value="447"/>
                <count group_id="O5" value="424"/>
                <count group_id="O6" value="453"/>
                <count group_id="O7" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, POST (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" lower_limit="11.31" upper_limit="13.82"/>
                    <measurement group_id="O2" value="12.12" lower_limit="10.67" upper_limit="13.77"/>
                    <measurement group_id="O3" value="14.20" lower_limit="12.83" upper_limit="15.71"/>
                    <measurement group_id="O4" value="12.52" lower_limit="11.07" upper_limit="14.17"/>
                    <measurement group_id="O5" value="14.56" lower_limit="13.20" upper_limit="16.05"/>
                    <measurement group_id="O6" value="14.29" lower_limit="12.52" upper_limit="16.31"/>
                    <measurement group_id="O7" value="11.95" lower_limit="10.52" upper_limit="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, POST (N=423;453;423;447;423;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" lower_limit="6.30" upper_limit="7.84"/>
                    <measurement group_id="O2" value="8.91" lower_limit="7.85" upper_limit="10.11"/>
                    <measurement group_id="O3" value="6.82" lower_limit="6.09" upper_limit="7.64"/>
                    <measurement group_id="O4" value="7.94" lower_limit="7.02" upper_limit="8.97"/>
                    <measurement group_id="O5" value="7.29" lower_limit="6.51" upper_limit="8.16"/>
                    <measurement group_id="O6" value="8.27" lower_limit="7.32" upper_limit="9.34"/>
                    <measurement group_id="O7" value="10.94" lower_limit="9.64" upper_limit="12.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria, POST (N=423;453;423;447;423;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.64" lower_limit="9.41" upper_limit="12.02"/>
                    <measurement group_id="O2" value="9.65" lower_limit="8.42" upper_limit="11.07"/>
                    <measurement group_id="O3" value="9.75" lower_limit="8.61" upper_limit="11.04"/>
                    <measurement group_id="O4" value="9.28" lower_limit="8.04" upper_limit="10.71"/>
                    <measurement group_id="O5" value="2.85" lower_limit="2.58" upper_limit="3.16"/>
                    <measurement group_id="O6" value="2.44" lower_limit="2.25" upper_limit="2.65"/>
                    <measurement group_id="O7" value="14.61" lower_limit="12.84" upper_limit="16.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata, POST (N=423;453;423;447;424;453;259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.23" lower_limit="11.74" upper_limit="14.90"/>
                    <measurement group_id="O2" value="6.09" lower_limit="5.42" upper_limit="6.84"/>
                    <measurement group_id="O3" value="3.49" lower_limit="3.18" upper_limit="3.84"/>
                    <measurement group_id="O4" value="3.26" lower_limit="2.93" upper_limit="3.62"/>
                    <measurement group_id="O5" value="14.11" lower_limit="12.57" upper_limit="15.84"/>
                    <measurement group_id="O6" value="5.63" lower_limit="5.02" upper_limit="6.33"/>
                    <measurement group_id="O7" value="24.92" lower_limit="21.98" upper_limit="28.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Vaccination</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity grade. Grade 3 pain for subjects &lt; 5 years of age = Cried when limb was moved/spontaneously painful; Grade 3 pain for subjects ≥ 5 years of age = Significant pain at rest, pain that preventeded normal everyday activities. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeters (mm).</description>
        <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Vaccination</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity grade. Grade 3 pain for subjects &lt; 5 years of age = Cried when limb was moved/spontaneously painful; Grade 3 pain for subjects ≥ 5 years of age = Significant pain at rest, pain that preventeded normal everyday activities. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="913"/>
                <count group_id="O2" value="912"/>
                <count group_id="O3" value="916"/>
                <count group_id="O4" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637"/>
                    <measurement group_id="O2" value="538"/>
                    <measurement group_id="O3" value="542"/>
                    <measurement group_id="O4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited Local Symptoms After Vaccination</title>
        <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2 respectively. Solicited local symptoms assessed for duration were pain, redness and swelling.</description>
        <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Solicited Local Symptoms After Vaccination</title>
          <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2 respectively. Solicited local symptoms assessed for duration were pain, redness and swelling.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="497"/>
                <count group_id="O3" value="510"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain, Dose 1 (N=597;497;510;131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Dose 2 (N=169;151;141;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Dose 1 (N=48;29;32;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Dose 2 (N=13;11;10;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.5" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Dose 1 (N=57;30;35;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Dose 2 (N=12;15;7;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Below 5 Years of Age With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Symptoms assessed were drowsiness, irritability, loss of appetite and temperature. Any = Incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Any temperature = Axillary temperature ≥ 38.0 degrees Celsius (°C). Grade 3 temperature = Axillary temperature ≥ 39.0°C. Grade 3 irritability = Crying that could not be comforted/ preventing normal activity. Grade 3 drowsiness = Drowsiness preventing normal activity. Grade 3 loss of appetite = Not eating at all. Related = A general symptom assessed by the investigator as causally related to vaccination.</description>
        <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Below 5 Years of Age With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Symptoms assessed were drowsiness, irritability, loss of appetite and temperature. Any = Incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Any temperature = Axillary temperature ≥ 38.0 degrees Celsius (°C). Grade 3 temperature = Axillary temperature ≥ 39.0°C. Grade 3 irritability = Crying that could not be comforted/ preventing normal activity. Grade 3 drowsiness = Drowsiness preventing normal activity. Grade 3 loss of appetite = Not eating at all. Related = A general symptom assessed by the investigator as causally related to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects 5 Years of Age and Above With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering and temperature. Any = Incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Any temperature = axillary temperature ≥ 38.0 °C. Grade 3 temperature = axillary temperature ≥ 39.0°C. Grade 3 symptom = Symptom that prevented normal activity. Related = A general symptom assessed by the investigator as causally related to vaccination.</description>
        <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects 5 Years of Age and Above With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering and temperature. Any = Incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Any temperature = axillary temperature ≥ 38.0 °C. Grade 3 temperature = axillary temperature ≥ 39.0°C. Grade 3 symptom = Symptom that prevented normal activity. Related = A general symptom assessed by the investigator as causally related to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="727"/>
                <count group_id="O2" value="725"/>
                <count group_id="O3" value="726"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any joint pain at other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 joint pain at other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related joint pain at other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="178"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited General Symptoms After Vaccination in Subjects Below 5 Years of Age</title>
        <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2, respectively. Solicited general symptoms assessed for duration in subjects below 5 years of age were drowsiness, irritability and loss of appetite.</description>
        <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Solicited General Symptoms After Vaccination in Subjects Below 5 Years of Age</title>
          <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2, respectively. Solicited general symptoms assessed for duration in subjects below 5 years of age were drowsiness, irritability and loss of appetite.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness, Dose 1 (N=39;37;44;85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness, Dose 2 (N=16;18;17;45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability, Dose 1 (N=48;31;41;120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability, Dose 2 (N=25;22;16;74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.5"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite, Dose 1 (N=32;30;25;64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite, Dose 2 (N=13;15;14;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited General Symptoms After Vaccination in Subjects 5 Years of Age and Above</title>
        <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2, respectively. Solicited general symptoms assessed for duration in subjects 5 years of age and above were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches and shivering.</description>
        <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Solicited General Symptoms After Vaccination in Subjects 5 Years of Age and Above</title>
          <description>Duration was assessed via tabulation of the number of days with local symptoms of any grade after vaccination with Dose 1 and Dose 2, respectively. Solicited general symptoms assessed for duration in subjects 5 years of age and above were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches and shivering.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue, Dose 1 (N=161;171;167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Dose 2 (N=27;19;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms, Dose 1 (N=70;70;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms, Dose 2 (N=17;16;9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Dose 1 (160;160;146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Dose 2 (20;19;17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain at other location, Dose 1 (N=94;86;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain at other location, Dose 2 (N=21;13;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches, Dose 1 (N=207;180;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches, Dose 2 (N=44;27;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering, Dose 1 (N=51;50;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering, Dose 2 (N=8;1;4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Fever in All Subjects Regardless of Their Age After Vaccination</title>
        <description>Duration for fever was assessed via tabulation of the number of days with local symptoms of fever (axillary temperature ≥ 38°C) after vaccination with Dose 1 and Dose 2, respectively.</description>
        <time_frame>During the 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Fever in All Subjects Regardless of Their Age After Vaccination</title>
          <description>Duration for fever was assessed via tabulation of the number of days with local symptoms of fever (axillary temperature ≥ 38°C) after vaccination with Dose 1 and Dose 2, respectively.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented, solely on subjects with symptom sheet completed for the reported specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever, Dose 1 (N=25;43;26;16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, Dose 2 (N=17;7;9;12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE(s) = Occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 unsolicited AE = Occurrence of any unsolicited AE that prevented normal activities. Related unsolicited AE(s) = Occurrence of an unsolicited AE assessed by the investigator to be causally related to vaccination.</description>
        <time_frame>During the 28-day follow-up period (Day 0-27) after vaccination</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE(s) = Occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 unsolicited AE = Occurrence of any unsolicited AE that prevented normal activities. Related unsolicited AE(s) = Occurrence of an unsolicited AE assessed by the investigator to be causally related to vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="932"/>
                <count group_id="O2" value="929"/>
                <count group_id="O3" value="932"/>
                <count group_id="O4" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="291"/>
                    <measurement group_id="O3" value="275"/>
                    <measurement group_id="O4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs) After Vaccination</title>
        <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Any pIMD(s) = Occurrence of any pIMD(s) regardless of intensity grade or relation to vaccination. Related pIMD(s) = pIMD assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the entire study period (from Day 0 to Day 180)</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs) After Vaccination</title>
          <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Any pIMD(s) = Occurrence of any pIMD(s) regardless of intensity grade or relation to vaccination. Related pIMD(s) = pIMD assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="932"/>
                <count group_id="O2" value="929"/>
                <count group_id="O3" value="932"/>
                <count group_id="O4" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Medically-attended Adverse Events (MAEs) After Vaccination</title>
        <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other criterion for serious adverse event (SAE)), it was reported as SAE. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.Relationship to vaccination was not assessed for MAEs.</description>
        <time_frame>During the entire study period (from Day 0 to Day 180)</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Medically-attended Adverse Events (MAEs) After Vaccination</title>
          <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other criterion for serious adverse event (SAE)), it was reported as SAE. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.Relationship to vaccination was not assessed for MAEs.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="932"/>
                <count group_id="O2" value="929"/>
                <count group_id="O3" value="932"/>
                <count group_id="O4" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="335"/>
                    <measurement group_id="O3" value="350"/>
                    <measurement group_id="O4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE(s) = Occurrence of any SAE(s) regardless of intensity grade or relation to vaccination. Related SAE(s)= Occurrence of any SAE(s) assessed by the investigator as causally related to vaccination.</description>
        <time_frame>During the entire study period (from Day 0 to Day 180)</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain Fluarix Group</title>
            <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE(s) = Occurrence of any SAE(s) regardless of intensity grade or relation to vaccination. Related SAE(s)= Occurrence of any SAE(s) assessed by the investigator as causally related to vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="932"/>
                <count group_id="O2" value="929"/>
                <count group_id="O3" value="932"/>
                <count group_id="O4" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed from Day 0 to Day 180. Systematically and non-systematically assessed frequent adverse events (AEs) were assessed during a 7-day and 28-day post-vaccination period, respectively.</time_frame>
      <desc>For the systematically-assessed other non-serious AEs, the number of participants at risk included those from Total Vaccinated cohort whose symptom sheet had been completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK2282512A 1 Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Victoria Strain Fluarix Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Yamagata Strain Fluarix Group</title>
          <description>Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>GSK2282512A 2 Group</title>
          <description>Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants &lt;12 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="637" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="538" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="542" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="637" subjects_at_risk="913"/>
                <counts group_id="E2" subjects_affected="538" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="542" subjects_at_risk="916"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="913"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="916"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="913"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="916"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <description>Assessed in subjects less than 5 years of age in all study Groups.</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Assessed in subjects less than 5 years of age in all study Groups.</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="141" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>Assessed in subjects less than 5 years of age in all study Groups.</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <description>Assessed in subjects less than 5 years of age in all study Groups.</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Assessed in subjects 5 years of age and above in GSK2282512A 1 Group, Victoria strain Fluarix Group and Yamagata strain Fluarix Group.</description>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="725"/>
                <counts group_id="E3" subjects_affected="177" subjects_at_risk="726"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>Assessed in subjects 5 years of age and above in GSK2282512A 1 Group, Victoria strain Fluarix Group and Yamagata strain Fluarix Group.</description>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="725"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="726"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Assessed in subjects 5 years of age and above in GSK2282512A 1 Group, Victoria strain Fluarix Group and Yamagata strain Fluarix Group.</description>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="725"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="726"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Joint pain at other location</sub_title>
                <description>Assessed in subjects 5 years of age and above in GSK2282512A 1 Group, Victoria strain Fluarix Group and Yamagata strain Fluarix Group.</description>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="725"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="726"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <description>Assessed in subjects 5 years of age and above in GSK2282512A 1 Group, Victoria strain Fluarix Group and Yamagata strain Fluarix Group.</description>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="725"/>
                <counts group_id="E3" subjects_affected="193" subjects_at_risk="726"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <description>Assessed in subjects 5 years of age and above in GSK2282512A 1 Group, Victoria strain Fluarix Group and Yamagata strain Fluarix Group.</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="727"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="725"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="726"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="932"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="929"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="932"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

